AR103954A1 - Análogos de amilina - Google Patents
Análogos de amilinaInfo
- Publication number
- AR103954A1 AR103954A1 ARP160100708A ARP160100708A AR103954A1 AR 103954 A1 AR103954 A1 AR 103954A1 AR P160100708 A ARP160100708 A AR P160100708A AR P160100708 A ARP160100708 A AR P160100708A AR 103954 A1 AR103954 A1 AR 103954A1
- Authority
- AR
- Argentina
- Prior art keywords
- ser
- thr
- group
- val
- asn
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
Abstract
La presente divulgación se refiere a análogos de amilina y a su uso en el tratamiento y/o la prevención de una multiplicidad de afecciones, estados o trastornos, incluyendo obesidad, consumo excesivo de alimentos y enfermedades metabólicas relacionadas tal como diabetes. Los análogos presentan una buena estabilidad física y química y una acción prolongada y se adecuan bien para su uso en la forma de una formulación líquida. Reivindicación 1: Un análogo de amilina que es un compuesto que presenta la fórmula: R¹-Z-R² en el que R¹ es hidrógeno, acilo C₁₋₄, benzoílo o alquilo C₁₋₄ o un grupo M que prolonga la vida media, en donde M opcionalmente está enlazado con Z por medio de una fracción de enlace L; R² es OH o NHR³, en el que R³ es hidrógeno o alquilo C₁₋₃; y Z es una secuencia de aminoácidos de fórmula (1): Arg-Cys-X³-Thr-Ala-Thr-Cys-Ala-Thr-X¹⁰-Arg-Leu-Ala-X¹⁴-Phe-Leu-X¹⁷-Arg-X¹⁹-X²⁰-Phe-Gly(Me)-Ala-lle(Me)-Leu-Ser-Ser-Thr-X³¹-Val-Gly-Ser-X³⁵-Thr-X³⁷ (1) (ID SEC Nº 3); en donde X³ es seleccionado del grupo que consiste de Asn, Gly, Pro y Gln; X¹⁰ es seleccionado del grupo que consiste de Gln, Asp y Glu; X¹⁴ es seleccionado del grupo que consiste de Asp, His, Asn y Aad; X¹⁷ es seleccionado del grupo que consiste de His, Asn, Gln, Glu, Thr, Val, Lys y Aad; X¹⁹-X²⁰ es seleccionado del grupo que consiste de Ser-Ser, Val-Val, Ser-Val y Val-Ser o no está presente; X³¹ es seleccionado del grupo que consiste de Asp, Glu y Asn; X³⁵ es seleccionado del grupo que consiste de Asp, Glu, Asn, Ser, Phe, Orn, Aad, Gly y Thr; y X³⁷ es seleccionado del grupo que consiste de Pro, Apr y Hyp; y en donde el compuesto tiene al menos un resto seleccionado de: X³ es Gln; X¹⁴ es His, Asn o Aad; X¹⁷ es Asn, Gln, Glu, Thr o Aad; X¹⁹-X²⁰ es Val-Ser o Ser-Val; y X³⁵ es Ser, Phe, Orn, Aad, Gly o Thr; o una sal o un solvato de las mismas farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15159737 | 2015-03-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103954A1 true AR103954A1 (es) | 2017-06-14 |
Family
ID=52779493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100708A AR103954A1 (es) | 2015-03-18 | 2016-03-17 | Análogos de amilina |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10766939B2 (es) |
| EP (1) | EP3271381B1 (es) |
| JP (1) | JP6769984B2 (es) |
| KR (1) | KR20170126504A (es) |
| CN (1) | CN107567459B (es) |
| AR (1) | AR103954A1 (es) |
| AU (1) | AU2016232218B2 (es) |
| BR (1) | BR112017019378A2 (es) |
| CA (1) | CA2979950A1 (es) |
| CL (1) | CL2017002256A1 (es) |
| CO (1) | CO2017008870A2 (es) |
| EA (1) | EA035791B1 (es) |
| IL (1) | IL253924A0 (es) |
| MX (1) | MX2017011182A (es) |
| PE (1) | PE20180497A1 (es) |
| PH (1) | PH12017501674A1 (es) |
| SG (1) | SG11201707286UA (es) |
| TW (1) | TW201706294A (es) |
| WO (1) | WO2016146739A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016146739A1 (en) | 2015-03-18 | 2016-09-22 | Zealand Pharma A/S | Amylin analogues |
| TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
| AU2020384729A1 (en) | 2019-11-11 | 2022-04-14 | Boehringer Ingelheim International Gmbh | NPY2 receptor agonists |
| KR20230040943A (ko) * | 2020-04-20 | 2023-03-23 | 아이투오 테라퓨틱스, 인코포레이티드 | 1형 당뇨병에 대한 우수한 혈당 제어를 제공하기 위한 인간 아밀린 유사체 폴리펩타이드의 용도 |
| BR112022025623A2 (pt) | 2020-08-07 | 2023-03-07 | Boehringer Ingelheim Int | Agonistas solúveis de receptores de npy2 |
| FI4021929T3 (fi) | 2020-09-24 | 2023-06-14 | Gubra Aps | HAM15-52-analogeja, joilla on parannettu teho amyliinireseptoriin (HAMY3R) |
| EP4144362A1 (en) | 2021-09-06 | 2023-03-08 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| WO2022248419A2 (en) | 2021-05-22 | 2022-12-01 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4129324A1 (en) | 2021-08-02 | 2023-02-08 | Adocia | Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist |
| CN113893349B (zh) * | 2021-12-13 | 2022-07-22 | 北京大学第三医院（北京大学第三临床医学院） | 达格列净及其类似物在制备防治雄性生殖功能障碍的药物中的用途 |
| WO2023227133A1 (zh) * | 2022-05-27 | 2023-11-30 | 杭州先为达生物科技股份有限公司 | 人胰淀素类似物、其衍生物及用途 |
| WO2023232781A1 (en) * | 2022-05-30 | 2023-12-07 | Zealand Pharma A/S | Liquid formulations of amylin analogues |
| WO2024022465A1 (zh) * | 2022-07-29 | 2024-02-01 | 杭州九源基因工程有限公司 | 一种人胰淀素多肽衍生物及其用途 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5175146A (en) | 1989-12-05 | 1992-12-29 | Vical, Inc. | Synthetic calcitonin peptides |
| US5234906A (en) | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
| CA2100745C (en) * | 1991-11-19 | 2007-07-31 | Laura S. L. Gaeta | Amylin agonist peptides and uses therefor |
| RU2177331C2 (ru) | 1993-09-07 | 2001-12-27 | Амилин Фармасьютикалз, Инк. | Способы регулирования моторики желудочно-кишечного тракта |
| CA2468374C (en) | 1996-08-30 | 2010-12-21 | Novo-Nordisk A/S | Glp-1 derivatives |
| ES2239364T3 (es) | 1996-09-09 | 2005-09-16 | Zealand Pharma A/S | Sintesis de peptidos en fase solida. |
| US5677279A (en) | 1996-12-16 | 1997-10-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating pain with amylin or agonists thereof |
| US7101853B2 (en) | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
| US7910548B2 (en) | 1997-06-06 | 2011-03-22 | Amylin Pharmaceuticals, Inc. | Methods for treating obesity |
| WO1999034764A2 (en) | 1998-01-09 | 1999-07-15 | Amylin Pharmaceuticals, Inc. | Amylin agonist pharmaceutical compositions containing insulin |
| US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
| CN1344248A (zh) | 1999-03-17 | 2002-04-10 | 诺沃挪第克公司 | 肽的酰化方法和新酰化剂 |
| US8008255B2 (en) | 2003-05-30 | 2011-08-30 | Amylin Pharmaceuticals, Inc. | Methods and compositions for enhanced transmucosal delivery of peptides and proteins |
| AU2005320351B2 (en) | 2004-02-11 | 2010-06-03 | Amylin Pharmaceuticals, Llc | Amylin family peptides and methods for making and using them |
| EP2422807A3 (en) | 2004-02-11 | 2012-05-30 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
| DE102004051014A1 (de) | 2004-10-20 | 2006-04-27 | Rwth Aachen | Chemisch modifizierte Peptidanaloga |
| US20090286723A1 (en) | 2005-02-11 | 2009-11-19 | Amylin Pharmaceuticals, Inc. | Hybrid Polypeptides with Selectable Properties |
| US8486890B2 (en) | 2006-03-15 | 2013-07-16 | Novo Nordisk A/S | Amylin derivatives |
| EP2487184A1 (en) | 2007-02-15 | 2012-08-15 | Indiana University Research and Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| EP2158214B1 (en) | 2007-06-15 | 2011-08-17 | Zealand Pharma A/S | Glucagon analogues |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| JP5703226B2 (ja) | 2008-10-21 | 2015-04-15 | ノヴォ ノルディスク アー／エス | アミリン誘導体 |
| KR20110126591A (ko) | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| AU2008365559B2 (en) | 2008-12-15 | 2016-02-25 | Zealand Pharma A/S | Glucagon analogues |
| CN102292347A (zh) | 2008-12-15 | 2011-12-21 | 西兰制药公司 | 胰高血糖素类似物 |
| EP2799447B1 (en) | 2008-12-15 | 2016-11-23 | Zealand Pharma A/S | Glucagon analogues |
| WO2010107874A2 (en) | 2009-03-17 | 2010-09-23 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition using amylin agonists |
| HUE026255T2 (en) | 2009-07-13 | 2016-06-28 | Zealand Pharma As | Acylated glucagon analogues |
| WO2011064282A1 (en) | 2009-11-25 | 2011-06-03 | Novo Nordisk A/S | Method for making polypeptides |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| CA2802897A1 (en) | 2010-06-24 | 2011-12-29 | Zealand Pharma A/S | Glucagon analogues |
| EP2718314A2 (en) * | 2011-06-10 | 2014-04-16 | Novo Nordisk A/S | Polypeptides |
| KR20140114845A (ko) | 2011-12-23 | 2014-09-29 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| JP6227629B2 (ja) * | 2012-04-19 | 2017-11-08 | ノヴォ ノルディスク アー／エス | ヒトアミリン類似体 |
| US8575091B1 (en) | 2012-04-19 | 2013-11-05 | Novo Nordisk A/S | Amylin analogues and pharmaceutical compositions thereof |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| JP2016208556A (ja) * | 2013-10-03 | 2016-12-08 | 三菱電機株式会社 | デマンド予測装置及びデマンド予測方法 |
| DK3137494T3 (da) | 2014-05-02 | 2021-10-04 | Univ New York State Res Found | Isletamyloidpolypeptider med forbedret opløselighed |
| WO2016034604A1 (en) | 2014-09-04 | 2016-03-10 | Novo Nordisk A/S | Novel amylin and calcitonin receptor agonist |
| WO2016146739A1 (en) | 2015-03-18 | 2016-09-22 | Zealand Pharma A/S | Amylin analogues |
| TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
-
2016
- 2016-03-17 WO PCT/EP2016/055793 patent/WO2016146739A1/en active Application Filing
- 2016-03-17 PE PE2017001497A patent/PE20180497A1/es unknown
- 2016-03-17 EA EA201791617A patent/EA035791B1/ru unknown
- 2016-03-17 CN CN201680015858.2A patent/CN107567459B/zh active Active
- 2016-03-17 BR BR112017019378-7A patent/BR112017019378A2/pt not_active IP Right Cessation
- 2016-03-17 JP JP2017548895A patent/JP6769984B2/ja active Active
- 2016-03-17 SG SG11201707286UA patent/SG11201707286UA/en unknown
- 2016-03-17 AU AU2016232218A patent/AU2016232218B2/en not_active Ceased
- 2016-03-17 AR ARP160100708A patent/AR103954A1/es unknown
- 2016-03-17 MX MX2017011182A patent/MX2017011182A/es unknown
- 2016-03-17 EP EP16713772.8A patent/EP3271381B1/en active Active
- 2016-03-17 CA CA2979950A patent/CA2979950A1/en not_active Abandoned
- 2016-03-17 KR KR1020177029942A patent/KR20170126504A/ko unknown
- 2016-03-18 TW TW105108579A patent/TW201706294A/zh unknown
- 2016-03-18 US US15/074,526 patent/US10766939B2/en active Active
-
2017
- 2017-08-09 IL IL253924A patent/IL253924A0/en unknown
- 2017-08-30 CO CONC2017/0008870A patent/CO2017008870A2/es unknown
- 2017-09-06 CL CL2017002256A patent/CL2017002256A1/es unknown
- 2017-09-13 PH PH12017501674A patent/PH12017501674A1/en unknown
-
2020
- 2020-08-06 US US16/986,790 patent/US20210115104A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN107567459B (zh) | 2021-09-24 |
| US20160272693A1 (en) | 2016-09-22 |
| CA2979950A1 (en) | 2016-09-22 |
| EP3271381B1 (en) | 2021-09-08 |
| EA035791B1 (ru) | 2020-08-11 |
| CO2017008870A2 (es) | 2017-11-10 |
| KR20170126504A (ko) | 2017-11-17 |
| EA201791617A1 (ru) | 2018-02-28 |
| CN107567459A (zh) | 2018-01-09 |
| JP6769984B2 (ja) | 2020-10-14 |
| US10766939B2 (en) | 2020-09-08 |
| PE20180497A1 (es) | 2018-03-09 |
| CL2017002256A1 (es) | 2018-04-02 |
| AU2016232218B2 (en) | 2020-09-10 |
| US20210115104A1 (en) | 2021-04-22 |
| MX2017011182A (es) | 2018-06-06 |
| EP3271381A1 (en) | 2018-01-24 |
| BR112017019378A2 (pt) | 2019-02-19 |
| PH12017501674A1 (en) | 2018-03-12 |
| WO2016146739A1 (en) | 2016-09-22 |
| AU2016232218A1 (en) | 2017-09-21 |
| TW201706294A (zh) | 2017-02-16 |
| JP2018510871A (ja) | 2018-04-19 |
| SG11201707286UA (en) | 2017-10-30 |
| IL253924A0 (en) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103954A1 (es) | Análogos de amilina | |
| PE20240015A1 (es) | Proteinas de fusion gdf15 y usos de estas | |
| AR091866A1 (es) | Analogos del glucagon | |
| EA201990360A1 (ru) | Аналоги амилина | |
| EA201890618A1 (ru) | Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами | |
| AR114971A1 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
| EA201690494A1 (ru) | Ацилированные аналоги глюкагона | |
| SV2009003422A (es) | Acidos benzoilamino-indan-2-carboxilicos sustituidos y compuestos relacionados | |
| BR112015023448A2 (pt) | compostos e composições para o tratamento de doenças parasíticas | |
| NI201800051A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer | |
| AR092873A1 (es) | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon | |
| TR201903492T4 (tr) | Apomorfin ve organik asitler içeren bileşimler ve bunların kullanım alanları. | |
| UA107174C2 (uk) | Кристалічні форми саксагліптину та процес їх одержання (варіанти) | |
| AR090596A1 (es) | Formulaciones farmaceuticas que comprenden antagonistas de ccr3 | |
| BRPI0710485B8 (pt) | composições líquidas úteis no tratamento de doenças respiratórias | |
| CO2018012258A2 (es) | Compuestos de mic-1 y usos de estos | |
| AR079050A1 (es) | Compuestos benzoimidazolicos y sus usos | |
| DOP2017000287A (es) | Analogos glp-1 lipidados resistentes a proteasa | |
| PE20201254A1 (es) | Analogos de compstatina y sus usos medicos | |
| AR104751A1 (es) | Derivado de urea o una sal de este aceptable desde el punto de vista farmacológico | |
| EA201790223A1 (ru) | Водный препарат, содержащий парацетамол и ибупрофен | |
| BR112013032088A2 (pt) | "polipeptídeo, composição farmacêutica e seu uso" | |
| AR103254A1 (es) | Profármacos de creatina, composiciones y métodos de uso de estos | |
| AR089860A1 (es) | Analogos de la grelina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |